MEMORANDUM FOR ST
ATTN: MAJ CHARLES ANTON FRIES

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled *Enzyme Triggered Drug Delivery for Graft Targeted Immunosuppression and Neuroregeneration after VCA* presented at/published to *Association of Surgeons Great Britain and Ireland* 11-13 May 2016 with MDWI 41-108, and has been assigned local file #16195.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

Warrior Medics – Mission Ready – Patient Focused
**INSTRUCTIONS**

**USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING**

1. The author must complete page two of this form:
   a. In Section 2, add the funding source for your study (e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SGS O&M); SGS R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH, Congressionally Directed Medical Research Program (CDMRP); Grants, etc.)
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.

2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.

6. On page 2, have either your unit commander, program director or immediate supervisor:
   a. Print their name, rank/grade, title, sign and date the form in the approving authority’s signature block or use an electronic signature.

7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). If you have any questions or concerns, please contact the 59 CRD/ Publications and Presentations Section at 292-7141 for assistance.

8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDWIPA) for review and then forward you a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. **Note:** For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDWICC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDW 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.

**NOTE:** All abstracts, papers, posters, etc., should contain the following disclaimer statement:

> "The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

**NOTE:** All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

> "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AF 40-402."

**NOTE:** All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401 IP:

> "The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

---

**PREVIOUS EDITIONS CURRENTLY IN USE CAN BE USED**

**ALL OTHERS ARE OBSOLETE**
Enzyme Triggered Development Agreement (CRADA).

Forelimb Allo-Transplantation in Swine (Sus scrofa) Umbrella Protocol for Optimization of Reconstruction of Battlefield Injuries Using the A

6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:
Enzyme Triggered Drug Delivery for Graft Targeted Immunosuppression and Neuroregeneration after VCA

7. FUNDING RECEIVED FOR THIS STUDY? □ YES □ NO FUNDING SOURCE: AFMSA/59 MDW ST

8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES? □ YES □ NO

9. IS THIS MATERIAL CLASSIFIED? □ YES □ NO

10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? □ YES □ NO

11. MATERIAL IS FOR: □ DOMESTIC RELEASE □ FOREIGN RELEASE

11a. PUBLICATION/JOURNAL (List intended publication/journal.)

11b. PUBLISHED ABSTRACT (List intended journal.)

11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)

11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)

Association of Surgeons of Great Britain and Ireland/11-13 May 2016

11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)

12. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC

DATE
May 10, 2016

13. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)
Corpus Raul S, raul.s.corpus.ctr@mail.mil

14. DUTY PHONE/PAGER NUMBER
2105394404

15. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript:

LAST NAME, FIRST NAME AND M.I., GRADE/RANK, SQUADRON/GROUP/OFFICE SYMBOL, INSTITUTION (If not 59 MDW)

a. Primary/Corresponding Author
Charles Anton Fries, O-4

b. Sharon Lawson
CTR

O-3
CTR
O-3

m. Kevin Wu
CTR

n. Michael R Davis
O-5


16. AUTHOR'S PRINTED NAME, RANK, GRADE
Charles Anton Fries, O-4

17. AUTHOR'S SIGNATURE

18. DATE
April 26, 2016

19. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE
Michael R Davis, Lt Col, Director-RESTOR, Deputy Commander

20. APPROVING AUTHORITY'S SIGNATURE

21. DATE
April 26, 2016
The presentation is approved. The presentation will require a legal ethics review since it will be given to a foreign audience.
Enzyme Triggered Drug Delivery for Graft Targeted Immunosuppression and Neuroregeneration after VCA

CA Fries, SD Lawson, LC Wang, R Cindass, K Wu, VS Gorantla, N Desai, J Fisher, J Karp, S Little, MR Davis

Sharon Lawson, MD
Research Fellow, RESTOR™ Program,
General Surgery Resident, UTHSCSA

RESTOR™ Program, 59th Medical Wing, JBSA Lackland AFB
Disclaimer

The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of Defense.

The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended.
Impact of Military Trauma Care and Research

- Improved combat casualty care
  - Increased injury severity score
  - Decreased case fatality rate

![Graph showing trends in injury severity score and case fatality rate in Afghanistan from 2005 to 2013.](image)
New rung on the reconstructive ladder

- Vascularized composite allotransplant
- Free tissue transfer (e.g., latissimus dorsi flap)
- Regional flaps (e.g., posterior interosseous)
- Local flap (e.g., rotational/transposition)
- Skin graft
- Secondary closure
- Primary closure

Vascularized Composite Allotransplantation (VCA)

- Current challenges and limitations
  - A life-enhancing but not a life-saving procedure
  - Requires lifelong systemic immunosuppression
    - Opportunistic infections: 88%
    - Metabolic complications: 70%
    - ≥1 episode of acute rejection within 1st year: 85%
  - Requires highly motivated patients to comply with immunosuppression
  - Limited donor pool

Background

- Forelimb model of VCA
  - analogous to human hand transplant

- Evaluation of a drug eluting hydrogel for localized immunosuppression
Enzyme Activated Drug Eluting Hydrogel

RESEARCH ARTICLE

TRANSPANTATION

A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft

Thusitha Gajanayake, Radu Olariu, Franck M. Leclère, Ashish Dhayani, Zijiang Yang, Anjan K. Bongoni, Yara Banz, Mihai A. Constantinescu, Jeffrey M. Karp, Praveen Kumar Vemula, Robert Rieben, Esther Vögelin

Currently, systemic immunosuppression is used in vascularized composite allotransplantation (VCA). This treatment has considerable side effects and reduces the quality of life of VCA recipients. We loaded the immunosuppressive drug tacrolimus into a self-assembled hydrogel, which releases the drug in response to proteolytic enzymes that are overexpressed during inflammation. A one-time local injection of the tacrolimus-laden hydrogel significantly prolonged graft survival in a Brown Norway-to-Lewis rat hindlimb transplantation model, leading to a median graft survival of >100 days compared to 33.5 days in tacrolimus only-treated recipients. Control groups with no treatment or hydrogel only showed a graft survival of 11 days. Histopathological evaluation, including anti-graft antibodies and complement C3, revealed significantly reduced immune responses in the tacrolimus-hydrogel group compared with tacrolimus only. In conclusion, a single-dose local injection of an enzyme-responsive tacrolimus-hydrogel is capable of preventing VCA rejection for >100 days in a rat model and may offer a new approach for immunosuppression in VCA.
Enzyme Activated Drug Eluting Hydrogel
Methods

• Three groups
  - Group 1: Controls – no immunosuppression
  - Group 2: High dose tacrolimus eluting hydrogel (81mg)
  - Group 3: Low dose tacrolimus eluting hydrogel (49mg)
• 1 swine leukocyte antigen (SLA) donor-recipient mismatch
• No systemic immunosuppression
• Hydrogel injected in the subcutaneous layer following revascularization
• AST, LDH, CK, TNF-a, IL-6, myoglobin, and biopsies were assessed for signs of systemic toxicity and/or acute rejection
• End-point – Banff grade 4 acute rejection or post-operative day 100
BANFF Rejection scale

- Grade 0
- Grade 4
Results

- Controls (2) – Grade IV Acute rejection mean POD 6
- Intervention (6) – Healed beyond POD 28 with no clinical or pathological rejection
Results: Rejection v. Time

High Dose Tacrolimus

- High Dose Tac 1
- High Dose Tac 2

Grade of Rejection vs. Time/Post-Op Day
Results: Rejection v. Time

Low Dose Tacrolimus

- Low Dose Tac 1
- Low Dose Tac 2
- Low Dose Tac 3
- Low Dose Tac 4

Grade of Rejection

Time/Post-Op Day
Results

Tacrolimus systemic levels

Time in days post transplantation

Tacrolimus in ng/ml
Nerve Conduction Study

- Initial nerve conduction studies
  - Performed on two low dose swine from POD 57
    - Software/Equipment: Grass Technologies S88 Dual Output, Square Pulse Stimulator, National Instruments USB-6009, Data Acquisition Board, LABVIEW
  - Conduction velocity in mid-distal limb approximately 20 m/s (nl 50-70 m/s)
Conclusions

- Graft embedded macrophage responsive hydrogels successfully achieved successful prevention of acute rejection in VCA.
  - prolongation of survival beyond 4 weeks
  - negligible / undetectable systemic tacrolimus levels
  - electrophysiologic evidence of nerve regeneration
Future direction

- Future hydrogel protocols
  - Optimize dosing regimen
  - Analyze gel depletion and re-loading of the gel
  - Increase survival duration to evaluate longer term rejection and side effects profile
Thank you

USAISR
Lt Col Michael Davis
Lt Col Dmitry Tuder
Dr Shari Lawson
Dr Kevin Wu
CPT Lin Wang
Mr Raul Corpus

Royal Centre for Defence Medicine
Surg Capt Mark Midwinter
Surg Capt Rory Rickard
Surg Lt Cdr C Anton Fries

59 Med Wing USAF
Mr JR Spencer

University of Pittsburgh Medical Center
Prof Vijay Gorontla

Brigham and Women’s Hospital
Dr Nitin Joshi
Dr Jeffrey Karp

InStem, Bangalore
Dr Praveen Vemula

NAMRU, San Antonio
Ms Carrie Crane
Ms Candice Angueira